Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial
Primary result · MACEResult — go to the resultHazard ratio .85 95% CI .58-1.24Authors' conclusion
Targeted vitamin D supplementation and ongoing titration did not significantly reduce major adverse CV events.
Study context
- Population
- Patients with myocardial infarction (MI)
- Participants
- 630 patients
- Comparison
- Targeted vitamin D3 supplementation vs usual care
- Primary endpoint
- MACE:
- Death
- MI
- HF hospitalization
- Stroke
- Follow-up
- Average 4.2 ± 2.0 years
Methodological detailspragmatic
- Pragmatic
Primary result
MACE
Hazard ratio
.85
95% CI .58-1.24
P = 0.40
By group
Vitamin Dvs Usual care
HR .85 (95% CI .58-1.24); P = 0.40
As reported in the abstract
Secondary outcomes
Death
HR .98 · P = 0.95
MI
HR .48 · P = 0.03
HF hospitalization
HR 1.21 · P = 0.65
| Outcome | Vitamin D | Usual care | HR | P value |
|---|---|---|---|---|
| Stroke | 1.6% | .9% | 1.69 | P = 0.47 |
Baseline 25(OH)D level
- 25(OH)D ≤ 40 ng/mL at baseline
- 87.0%
- Median baseline 25(OH)D 25 (IQR 18-33) ng/mL
Original publication
Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial. Eur Heart J. Published 7 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →